Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Duolingo Inc (DUOL) vs Medpace Holdings Inc (MEDP) Price & Performance

Duolingo IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Duolingo Inc vs Medpace Holdings Inc — how do they compare? Duolingo Inc trades at $150.3 (market cap $7.08B), while Medpace Holdings Inc trades at $614.63 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 2.4× Duolingo Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and Medpace Holdings Inc for 14 Days on average.

DUOLMEDP
Market Cap
$7.08B$16.82B
Volume
729,171223,093
Sector
TechnologyHealth
52-Week High
$341.08$630.19
52-Week Low
$90.03$393.42
Typical Hold Time
137 Days14 Days
Enterprise Value
$5.85B$16.44B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Duolingo Inc

Duolingo (DUOL) trades at $150.50, down 0.8% on the day, as the stock consolidates near key resistance at $151. The company demonstrates strong fundamental momentum with revenue reaching $1.04 billion in 2025 and net income surging to $414 million, representing a robust 39.9% margin. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $0.66 exceeding the $0.604 forecast. Technical indicators show a bullish moving average alignment while RSI levels suggest potential near-term consolidation.

Duolingo presents a compelling growth story with accelerating profitability and strong user engagement, though valuation multiples remain elevated. Key risks include increased competition in edtech and insider selling activity. Analyst consensus leans cautious with a $140.63 price target below current levels, suggesting potential near-term headwinds despite the company's operational excellence.

Medpace Holdings Inc

MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.

Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DUOL
23% Buy77% Sell
Avg holding period · 137 Days
MEDP
100% Buy0% Sell
Avg holding period · 14 Days

Top news

Latest headlines on both assets

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL →

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP →